Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) Announces First Grant of A Share Options Under 2025 Scheme

Bulletin Express

Nov 04

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) received shareholder approval for the 2025 A Share Option Scheme at an extraordinary general meeting on 23 October 2025. Subsequently, on 4 November 2025, the board resolved to grant a total of 4,535,100 A Share Options, corresponding to approximately 0.1698% of the total number of shares in issue as of the same date. The exercise price for these options is set at RMB27.93 per share.

A total of 195 participants are included in this first grant, following the departure of six initially proposed participants who are no longer employed by the group. Certain participants under this grant are connected persons, constituting connected transactions under Chapter 14A of the Hong Kong Listing Rules. However, as all applicable percentage ratios for each such grant are below 0.1%, the transactions qualify for a full exemption from shareholders’ approval, annual review, and disclosure requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1129657725"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129657725\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129657725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129657725","market":"hk","top_or_hot":-1,"title":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) Announces First Grant of A Share Options Under 2025 Scheme","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) received shareholder approval for the 2025 A Share Option Scheme at an extraordinary general meeting on 23 October 2025. Subsequently, on 4 November 2025, the board resolved to grant a total of 4,535,100 A Share Options, corresponding to approximately 0.1698% of the total number of shares in issue as of the same date. The exercise price for these options is set at RMB27.93 per share.</p>\n<p>A total of 195 participants are included in this first grant, following the departure of six initially proposed participants who are no longer employed by the group. Certain participants under this grant are connected persons, constituting connected transactions under Chapter 14A of the Hong Kong Listing Rules. However, as all applicable percentage ratios for each such grant are below 0.1%, the transactions qualify for a full exemption from shareholders’ approval, annual review, and disclosure requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) Announces First Grant of A Share Options Under 2025 Scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) Announces First Grant of A Share Options Under 2025 Scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-04 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) received shareholder approval for the 2025 A Share Option Scheme at an extraordinary general meeting on 23 October 2025. Subsequently, on 4 November 2025, the board resolved to grant a total of 4,535,100 A Share Options, corresponding to approximately 0.1698% of the total number of shares in issue as of the same date. The exercise price for these options is set at RMB27.93 per share.</p>\n<p>A total of 195 participants are included in this first grant, following the departure of six initially proposed participants who are no longer employed by the group. Certain participants under this grant are connected persons, constituting connected transactions under Chapter 14A of the Hong Kong Listing Rules. However, as all applicable percentage ratios for each such grant are below 0.1%, the transactions qualify for a full exemption from shareholders’ approval, annual review, and disclosure requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1129657725","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129657725","pubTimestamp":1762258925,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) received shareholder approval for the 2025 A Share Option Scheme at an extraordinary general meeting on 23 October 2025. Subsequently, on 4...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"上海复星医药（集团）股份有限公司(02196)公布2025计划首次授予A股购股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196) received shareholder approval for the 2025 A Share Option Scheme at an extraordinary general meeting on 23 October 2025. Subsequently, on 4 November 2025, the board resolved to grant a total of 4,535,100 A Share Options, corresponding to approximately 0.1698% of the total number of shares in issue as of the same date. The exercise price for these options is set at RMB27.93 per share.\nA total of 195 participants are included in this first grant, following the departure of six initially proposed participants who are no longer employed by the group. Certain participants under this grant are connected persons, constituting connected transactions under Chapter 14A of the Hong Kong Listing Rules. However, as all applicable percentage ratios for each such grant are below 0.1%, the transactions qualify for a full exemption from shareholders’ approval, annual review, and disclosure requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}